iwCLL 2019 | Evaluating acalabrutinib in CLL treatment

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, evaluates the use of acalabrutinib in chronic lymphocytic leukemia (CLL) treatment, in comparison to other therapies. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.